Symbols / EOLS $3.94 -1.75% Evolus, Inc.
EOLS Chart
About
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 256.34M |
| Enterprise Value | 357.51M | Income | -51.64M | Sales | 297.18M |
| Book/sh | -0.35 | Cash/sh | 0.83 | Dividend Yield | — |
| Payout | 0.00% | Employees | 334 | IPO | — |
| P/E | — | Forward P/E | 16.42 | PEG | — |
| P/S | 0.86 | P/B | -11.10 | P/C | — |
| EV/EBITDA | -11.88 | EV/Sales | 1.20 | Quick Ratio | 1.44 |
| Current Ratio | 1.90 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.80 | EPS next Y | 0.24 | EPS Growth | — |
| Revenue Growth | 14.40% | Earnings | 2026-05-06 | ROA | -10.25% |
| ROE | — | ROIC | — | Gross Margin | 66.33% |
| Oper. Margin | -0.32% | Profit Margin | -17.38% | Shs Outstand | 65.06M |
| Shs Float | 48.59M | Short Float | 11.95% | Short Ratio | 5.23 |
| Short Interest | — | 52W High | 13.18 | 52W Low | 3.86 |
| Beta | 1.01 | Avg Volume | 1.32M | Volume | 811.32K |
| Target Price | $14.67 | Recom | Strong_buy | Prev Close | $4.01 |
| Price | $3.94 | Change | -1.75% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-04 | reit | BTIG | Buy → Buy | $13 |
| 2026-02-03 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2026-01-22 | main | BTIG | Buy → Buy | $13 |
| 2026-01-13 | main | Stifel | Buy → Buy | $17 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-12-24 | reit | Needham | Hold → Hold | — |
| 2025-12-02 | main | Mizuho | Outperform → Outperform | $19 |
| 2025-09-08 | reit | BTIG | Buy → Buy | $18 |
| 2025-08-06 | main | BTIG | Buy → Buy | $18 |
| 2025-08-06 | down | Needham | Buy → Hold | $22 |
| 2025-08-06 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-05-08 | reit | Needham | Buy → Buy | $22 |
| 2025-04-17 | init | BTIG | — → Buy | $21 |
| 2025-04-10 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-04-09 | reit | Needham | Buy → Buy | $22 |
| 2025-03-05 | main | Barclays | Overweight → Overweight | $25 |
| 2025-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-03-05 | reit | Needham | Buy → Buy | $22 |
| 2025-02-14 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2025-01-27 | main | Barclays | Overweight → Overweight | $22 |
- Vanguard disaggregates holdings for Evolus (NASDAQ: EOLS) after internal realignment - Stock Titan hu, 26 Mar 2026 15
- How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance - Yahoo Finance hu, 12 Mar 2026 07
- Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com Fri, 27 Mar 2026 16
- Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock - Investing.com Wed, 18 Mar 2026 07
- Why Evolus Stock Soared Today - The Motley Fool Wed, 04 Mar 2026 08
- Insider Sale: See Remarks of $EOLS Sells 3,119 Shares - Quiver Quantitative Fri, 20 Mar 2026 23
- Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop - simplywall.st hu, 15 Jan 2026 08
- Evolus posts record rally after Q4 beat (EOLS:NASDAQ) - Seeking Alpha Wed, 04 Mar 2026 08
- Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates - Yahoo Finance ue, 03 Mar 2026 08
- 10 new Evolus employees receive stock awards that vest over 4 years - Stock Titan Fri, 20 Mar 2026 07
- $EOLS stock is down 12% today. Here's what we see in our data. | EOLS Stock News - Quiver Quantitative Wed, 14 Jan 2026 08
- David Moatazedi Sells 116,720 Shares of Evolus (NASDAQ:EOLS) Stock - marketbeat.com Wed, 18 Mar 2026 07
- Evolus (EOLS) executive sells 29,996 shares after PSU vesting - Stock Titan Wed, 18 Mar 2026 07
- How A New Price Target Is Shaping The Evolus (EOLS) Story - Yahoo Finance Mon, 26 Jan 2026 08
- Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings - Quiver Quantitative ue, 03 Mar 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
297.18
+11.61%
|
266.27
+31.76%
|
202.09
+35.98%
|
148.62
|
| Operating Revenue |
|
297.18
+11.61%
|
266.27
+31.76%
|
202.09
+35.98%
|
148.62
|
| Cost Of Revenue |
|
100.07
+19.17%
|
83.97
+30.16%
|
64.51
+9.64%
|
58.84
|
| Reconciled Cost Of Revenue |
|
95.67
+19.15%
|
80.29
+32.00%
|
60.83
+10.37%
|
55.11
|
| Gross Profit |
|
197.11
+8.12%
|
182.30
+32.52%
|
137.57
+53.24%
|
89.77
|
| Operating Expense |
|
234.71
+12.01%
|
209.54
+14.79%
|
182.55
+22.23%
|
149.35
|
| Research And Development |
|
9.58
+4.40%
|
9.17
-40.54%
|
15.43
+128.79%
|
6.74
|
| Selling General And Administration |
|
220.79
+11.49%
|
198.03
+20.06%
|
164.94
+16.29%
|
141.84
|
| Total Expenses |
|
334.78
+14.06%
|
293.51
+18.80%
|
247.06
+18.67%
|
208.19
|
| Operating Income |
|
-37.60
-38.06%
|
-27.23
+39.45%
|
-44.98
+24.51%
|
-59.58
|
| Total Operating Income As Reported |
|
-32.66
+5.08%
|
-34.41
+30.11%
|
-49.23
+24.64%
|
-65.33
|
| EBITDA |
|
-22.53
+9.90%
|
-25.00
+40.20%
|
-41.81
+31.15%
|
-60.72
|
| Normalized EBITDA |
|
-21.08
+15.67%
|
-25.00
+40.20%
|
-41.81
+31.15%
|
-60.72
|
| Reconciled Depreciation |
|
8.74
+45.23%
|
6.02
+2.61%
|
5.87
+30.46%
|
4.50
|
| EBIT |
|
-31.27
-0.80%
|
-31.02
+34.94%
|
-47.68
+26.90%
|
-65.22
|
| Total Unusual Items |
|
-1.44
|
0.00
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-1.44
|
0.00
|
0.00
|
0.00
|
| Special Income Charges |
|
-1.44
|
0.00
|
0.00
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
2.00
|
| Restructuring And Mergern Acquisition |
|
1.44
|
0.00
|
0.00
|
—
|
| Net Income |
|
-51.64
-2.42%
|
-50.42
+18.26%
|
-61.69
+17.10%
|
-74.41
|
| Pretax Income |
|
-50.96
-2.43%
|
-49.76
+19.11%
|
-61.51
+17.23%
|
-74.32
|
| Net Non Operating Interest Income Expense |
|
-17.76
-14.81%
|
-15.47
-19.27%
|
-12.97
-44.49%
|
-8.98
|
| Interest Expense Non Operating |
|
19.69
+5.12%
|
18.73
+35.45%
|
13.83
+52.05%
|
9.10
|
| Net Interest Income |
|
-17.76
-14.81%
|
-15.47
-19.27%
|
-12.97
-44.49%
|
-8.98
|
| Interest Expense |
|
19.69
+5.12%
|
18.73
+35.45%
|
13.83
+52.05%
|
9.10
|
| Interest Income Non Operating |
|
1.93
-40.82%
|
3.26
+279.42%
|
0.86
+622.69%
|
0.12
|
| Interest Income |
|
1.93
-40.82%
|
3.26
+279.42%
|
0.86
+622.69%
|
0.12
|
| Other Income Expense |
|
4.40
+162.41%
|
-7.05
-97.95%
|
-3.56
+38.22%
|
-5.76
|
| Other Non Operating Income Expenses |
|
5.84
+182.88%
|
-7.05
-97.95%
|
-3.56
+38.22%
|
-5.76
|
| Tax Provision |
|
0.68
+1.96%
|
0.66
+277.27%
|
0.18
+85.26%
|
0.10
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.30
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-51.64
-2.42%
|
-50.42
+18.26%
|
-61.69
+17.10%
|
-74.41
|
| Net Income From Continuing Operation Net Minority Interest |
|
-51.64
-2.42%
|
-50.42
+18.26%
|
-61.69
+17.10%
|
-74.41
|
| Net Income From Continuing And Discontinued Operation |
|
-51.64
-2.42%
|
-50.42
+18.26%
|
-61.69
+17.10%
|
-74.41
|
| Net Income Continuous Operations |
|
-51.64
-2.42%
|
-50.42
+18.26%
|
-61.69
+17.10%
|
-74.41
|
| Normalized Income |
|
-50.50
-0.16%
|
-50.42
+18.26%
|
-61.69
+17.10%
|
-74.41
|
| Net Income Common Stockholders |
|
-51.64
-2.42%
|
-50.42
+18.26%
|
-61.69
+17.10%
|
-74.41
|
| Diluted EPS |
|
-0.80
+1.23%
|
-0.81
+25.00%
|
-1.08
+18.80%
|
-1.33
|
| Basic EPS |
|
-0.80
+1.23%
|
-0.81
+25.00%
|
-1.08
+18.80%
|
-1.33
|
| Basic Average Shares |
|
64.47
+3.57%
|
62.25
+9.36%
|
56.92
+1.52%
|
56.06
|
| Diluted Average Shares |
|
64.47
+3.57%
|
62.25
+9.36%
|
56.92
+1.52%
|
56.06
|
| Diluted NI Availto Com Stockholders |
|
-51.64
-2.42%
|
-50.42
+18.26%
|
-61.69
+17.10%
|
-74.41
|
| Depreciation Amortization Depletion Income Statement |
|
4.34
+85.53%
|
2.34
+7.53%
|
2.18
+183.96%
|
0.77
|
| Depreciation And Amortization In Income Statement |
|
4.34
+85.53%
|
2.34
+7.53%
|
2.18
+183.96%
|
0.77
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
189.00
|
| Current Assets |
|
112.42
|
| Cash Cash Equivalents And Short Term Investments |
|
62.84
|
| Cash And Cash Equivalents |
|
62.84
|
| Other Short Term Investments |
|
—
|
| Receivables |
|
30.53
|
| Accounts Receivable |
|
30.53
|
| Gross Accounts Receivable |
|
32.02
|
| Allowance For Doubtful Accounts Receivable |
|
-1.49
|
| Inventory |
|
11.00
|
| Prepaid Assets |
|
5.70
|
| Other Current Assets |
|
2.36
|
| Total Non Current Assets |
|
76.58
|
| Net PPE |
|
7.85
|
| Gross PPE |
|
10.25
|
| Accumulated Depreciation |
|
-2.40
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
2.19
|
| Other Properties |
|
5.84
|
| Leases |
|
2.21
|
| Goodwill And Other Intangible Assets |
|
68.32
|
| Goodwill |
|
21.21
|
| Other Intangible Assets |
|
47.11
|
| Other Non Current Assets |
|
0.41
|
| Total Liabilities Net Minority Interest |
|
209.69
|
| Current Liabilities |
|
48.29
|
| Payables And Accrued Expenses |
|
35.88
|
| Payables |
|
13.10
|
| Accounts Payable |
|
4.27
|
| Current Accrued Expenses |
|
22.78
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
| Current Debt And Capital Lease Obligation |
|
1.38
|
| Current Capital Lease Obligation |
|
1.38
|
| Current Deferred Liabilities |
|
11.03
|
| Current Deferred Revenue |
|
11.03
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
161.40
|
| Long Term Debt And Capital Lease Obligation |
|
125.17
|
| Long Term Debt |
|
120.36
|
| Long Term Capital Lease Obligation |
|
4.81
|
| Tradeand Other Payables Non Current |
|
0.00
|
| Non Current Deferred Liabilities |
|
0.03
|
| Non Current Deferred Taxes Liabilities |
|
0.03
|
| Stockholders Equity |
|
-20.69
|
| Common Stock Equity |
|
-20.69
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
57.82
|
| Ordinary Shares Number |
|
57.82
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
538.72
|
| Retained Earnings |
|
-558.98
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.43
|
| Other Equity Adjustments |
|
-0.43
|
| Total Equity Gross Minority Interest |
|
-20.69
|
| Total Capitalization |
|
99.67
|
| Working Capital |
|
64.13
|
| Invested Capital |
|
99.67
|
| Total Debt |
|
126.55
|
| Net Debt |
|
57.52
|
| Capital Lease Obligations |
|
6.19
|
| Net Tangible Assets |
|
-89.01
|
| Tangible Book Value |
|
-89.01
|
| Current Notes Payable |
|
—
|
| Dueto Related Parties Current |
|
8.83
|
| Dueto Related Parties Non Current |
|
36.20
|
| Non Current Accrued Expenses |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-42.27
-134.82%
|
-18.00
+47.07%
|
-34.01
+59.95%
|
-84.91
|
| Cash Flow From Continuing Operating Activities |
|
-42.27
-134.82%
|
-18.00
+47.07%
|
-34.01
+59.95%
|
-84.91
|
| Net Income From Continuing Operations |
|
-51.64
-2.42%
|
-50.42
+18.26%
|
-61.69
+17.10%
|
-74.41
|
| Depreciation Amortization Depletion |
|
8.74
+45.23%
|
6.02
+2.61%
|
5.87
+30.46%
|
4.50
|
| Depreciation |
|
8.74
+45.23%
|
6.02
+2.61%
|
5.87
+30.46%
|
4.50
|
| Depreciation And Amortization |
|
8.74
+45.23%
|
6.02
+2.61%
|
5.87
+30.46%
|
4.50
|
| Other Non Cash Items |
|
-4.12
-149.35%
|
8.36
-14.72%
|
9.80
+43.28%
|
6.84
|
| Stock Based Compensation |
|
20.70
-6.99%
|
22.25
+35.22%
|
16.46
+51.92%
|
10.83
|
| Provisionand Write Offof Assets |
|
6.51
+166.03%
|
2.45
+70.07%
|
1.44
-9.89%
|
1.60
|
| Deferred Tax |
|
0.02
+200.00%
|
-0.02
-520.00%
|
0.01
+127.78%
|
-0.02
|
| Deferred Income Tax |
|
0.02
+200.00%
|
-0.02
-520.00%
|
0.01
+127.78%
|
-0.02
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-22.48
-238.49%
|
-6.64
-12.64%
|
-5.89
+82.79%
|
-34.25
|
| Change In Receivables |
|
-11.51
+41.29%
|
-19.60
-105.88%
|
-9.52
-1.41%
|
-9.39
|
| Changes In Account Receivables |
|
-11.51
+41.29%
|
-19.60
-105.88%
|
-9.52
-1.41%
|
-9.39
|
| Change In Inventory |
|
-11.12
-442.07%
|
3.25
-22.44%
|
4.19
+139.23%
|
-10.69
|
| Change In Prepaid Assets |
|
-0.35
-115.10%
|
2.35
+230.76%
|
-1.80
-252.37%
|
1.18
|
| Change In Payables And Accrued Expense |
|
3.74
-49.26%
|
7.37
+145.47%
|
3.00
+115.61%
|
-19.23
|
| Change In Accrued Expense |
|
-6.36
-191.20%
|
6.98
+73.63%
|
4.02
+119.90%
|
-20.20
|
| Change In Payable |
|
10.10
+2483.89%
|
0.39
+138.45%
|
-1.02
-205.06%
|
0.97
|
| Change In Account Payable |
|
10.10
+2483.89%
|
0.39
+138.45%
|
-1.02
-205.06%
|
0.97
|
| Change In Other Current Assets |
|
-2.47
-449.72%
|
0.71
+181.71%
|
-0.86
-117.80%
|
4.85
|
| Change In Other Current Liabilities |
|
-0.76
-5.87%
|
-0.72
+21.06%
|
-0.91
+7.16%
|
-0.98
|
| Investing Cash Flow |
|
-8.45
-75.24%
|
-4.82
-196.44%
|
-1.63
+44.64%
|
-2.94
|
| Cash Flow From Continuing Investing Activities |
|
-8.45
-75.24%
|
-4.82
-196.44%
|
-1.63
+44.64%
|
-2.94
|
| Net PPE Purchase And Sale |
|
-3.44
-133.76%
|
-1.47
-211.21%
|
-0.47
+70.77%
|
-1.62
|
| Purchase Of PPE |
|
-3.44
-133.76%
|
-1.47
-211.21%
|
-0.47
+70.77%
|
-1.62
|
| Capital Expenditure |
|
-8.45
-75.24%
|
-4.82
-196.44%
|
-1.63
+44.64%
|
-2.94
|
| Capital Expenditure Reported |
|
-5.01
-49.54%
|
-3.35
-190.38%
|
-1.15
+12.64%
|
-1.32
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Purchase Of Investment |
|
—
|
—
|
—
|
—
|
| Sale Of Investment |
|
—
|
—
|
—
|
0.00
|
| Financing Cash Flow |
|
17.34
-63.43%
|
47.41
+6.21%
|
44.64
+1176.72%
|
-4.15
|
| Cash Flow From Continuing Financing Activities |
|
17.34
-63.43%
|
47.41
+6.21%
|
44.64
+1176.72%
|
-4.15
|
| Net Issuance Payments Of Debt |
|
24.98
|
0.00
-100.00%
|
50.00
|
0.00
|
| Issuance Of Debt |
|
25.00
|
0.00
-100.00%
|
50.00
|
0.00
|
| Repayment Of Debt |
|
-0.01
|
0.00
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
25.00
|
0.00
-100.00%
|
50.00
|
0.00
|
| Long Term Debt Payments |
|
-0.01
|
0.00
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
24.98
|
0.00
-100.00%
|
50.00
|
0.00
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
51.21
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
1.16
-76.16%
|
4.88
+2013.42%
|
0.23
-57.14%
|
0.54
|
| Net Other Financing Charges |
|
-8.81
-1.53%
|
-8.68
-55.26%
|
-5.59
-19.32%
|
-4.68
|
| Changes In Cash |
|
-33.38
-235.74%
|
24.59
+173.06%
|
9.01
+109.79%
|
-92.00
|
| Effect Of Exchange Rate Changes |
|
0.25
+153.14%
|
-0.48
-431.11%
|
-0.09
+73.29%
|
-0.34
|
| Beginning Cash Position |
|
86.95
+38.37%
|
62.84
+16.53%
|
53.92
-63.13%
|
146.26
|
| End Cash Position |
|
53.83
-38.10%
|
86.95
+38.37%
|
62.84
+16.53%
|
53.92
|
| Free Cash Flow |
|
-50.72
-122.23%
|
-22.82
+35.96%
|
-35.63
+59.44%
|
-87.85
|
| Interest Paid Supplemental Data |
|
14.79
-15.69%
|
17.55
+38.06%
|
12.71
+58.87%
|
8.00
|
| Income Tax Paid Supplemental Data |
|
1.22
+417.02%
|
0.23
+100.85%
|
0.12
+53.95%
|
0.08
|
| Amortization Of Securities |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
0.00
-100.00%
|
51.21
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
51.21
|
0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-20 View
- 42026-03-20 View
- 42026-03-18 View
- 42026-03-18 View
- 8-K2026-03-13 View
- 10-K2026-03-03 View
- 8-K2026-03-03 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 42026-02-19 View
- 8-K2026-01-09 View
- 42025-12-29 View
- 42025-12-29 View
- 10-Q2025-11-05 View
- 8-K2025-11-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|